Abstract
A three-year open-label study of atomoxetine in adults with ADHD followed two multicenter, double-blind trials. In the double-blind trials, female gender and higher levels of emotional symptoms were associated with better outcome. Following a 4-week placebo washout period, 384 (of 536) subjects continued into the open-label study. 61% of subjects entering this open-label study remained after 6months at an average dose of 100mg/day. Subjects who had previously responded to double-blind atomoxetine achieved maximum response after 8weeks of open-label medication, but others continued to improve for 36weeks. Women improved more (7.7±6.4) than men (6.1±6.4) on the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) (P=.007) and the Conners' Adult ADHD Rating Scale (P=.03). Subjects with emotional dysregulation improved more than others on the WRAADDS (P=.001). Responders ultimately improved approximately 60% in attentional, hyperactive/impulsive, and emotional symptoms. Thirty-nine percent of atomoxetine double-blind non-responders became responders during open-label treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: ADHD Attention Deficit and Hyperactivity Disorders
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
